{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:23:45Z","timestamp":1787901825721,"version":"build-2784847793"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T00:00:00Z","timestamp":1478736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1038\/bjc.2016.358","type":"journal-article","created":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T23:47:44Z","timestamp":1478821664000},"page":"1457-1461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Acute interstitial nephritis related to immune checkpoint inhibitors"],"prefix":"10.1038","volume":"115","author":[{"given":"Julie","family":"Belliere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Ollier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Boulinguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Delas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ribes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Faguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,10]]},"reference":[{"key":"BFbjc2016358_CR1","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, Le DT, Lipson EJ, Glezerman IG, Wolchok J, Cornell LD, Feldman P, Stokes MB, Zapata SA, Hodi FS, Ott PA, Yamashita M, Leaf DE (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90: 638\u2013647.","journal-title":"Kidney Int"},{"key":"BFbjc2016358_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMc0904283","volume":"361","author":"F Fadel","year":"2009","unstructured":"Fadel F, El Karoui K, Knebelmann B (2009) Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 361: 211\u2013212.","journal-title":"N Engl J Med"},{"key":"BFbjc2016358_CR3","first-page":"4607","volume":"32","author":"PM Forde","year":"2012","unstructured":"Forde PM, Rock K, Wilson G, O\u2019Byrne KJ (2012) Ipilimumab-induced immune-related renal failure\u2014a case report. Anticancer Res 32: 4607\u20134608.","journal-title":"Anticancer Res"},{"key":"BFbjc2016358_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nm.4051","volume":"22","author":"A Gros","year":"2016","unstructured":"Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, Trebska-McGowan K, Wunderlich JR, Yang JC, Rosenberg SA (2016) Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 22: 433\u2013438.","journal-title":"Nat Med"},{"key":"BFbjc2016358_CR5","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10637-014-0092-7","volume":"32","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Gueutin V, Gharbi C, Mateus C, Robert C, Routier E, Thomas M, Baumelou A, Rouvier P (2014) Kidney injuries related to ipilimumab. Invest New Drugs 32: 769\u2013773.","journal-title":"Invest New Drugs"},{"key":"BFbjc2016358_CR6","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.kint.2015.11.028","volume":"89","author":"JM Kidd","year":"2016","unstructured":"Kidd JM, Gizaw AB (2016) Ipilimumab-associated minimal-change disease. Kidney Int 89: 720.","journal-title":"Kidney Int"},{"key":"BFbjc2016358_CR7","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1182\/blood-2005-06-2298","volume":"106","author":"KD Lute","year":"2005","unstructured":"Lute KD, May KF, Lu P, Zhang H, Kocak E, Mosinger B, Wolford C, Phillips G, Caligiuri MA, Zheng P, Liu Y (2005) Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood 106: 3127\u20133133.","journal-title":"Blood"},{"key":"BFbjc2016358_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/2326-6066.CIR-13-0146","volume":"2","author":"L Min","year":"2013","unstructured":"Min L, Hodi FS (2013) Anti-PD1 Following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res 2: 15\u201318.","journal-title":"Cancer Immunol Res"},{"key":"BFbjc2016358_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","volume":"68","author":"AC Shirali","year":"2016","unstructured":"Shirali AC, Perazella MA, Gettinger S (2016) Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis 68: 287\u2013291.","journal-title":"Am J Kidney Dis"},{"key":"BFbjc2016358_CR10","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1681\/ASN.2006050418","volume":"17","author":"Z Spanou","year":"2006","unstructured":"Spanou Z, Keller M, Britschgi M, Yawalkar N, Fehr T, Neuweiler J, Gugger M, Mohaupt M, Pichler WJ (2006) Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol 17: 2919\u20132927.","journal-title":"J Am Soc Nephrol"},{"key":"BFbjc2016358_CR11","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1097\/MJT.0b013e3182a32ddc","volume":"22","author":"B Thajudeen","year":"2015","unstructured":"Thajudeen B, Madhrira M, Bracamonte E, Cranmer LD (2015) Ipilimumab granulomatous interstitial nephritis. Am J Ther 22: e84\u2013e87.","journal-title":"Am J Ther"},{"key":"BFbjc2016358_CR12","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443\u20132454.","journal-title":"N Engl J Med"},{"key":"BFbjc2016358_CR13","doi-asserted-by":"publisher","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","volume":"8","author":"CJ Voskens","year":"2013","unstructured":"Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, G\u00f6ppner D, Dummer R, Heinzerling LM (2013) The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 8: e53745.","journal-title":"PLoS One"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2016358.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2016358","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2016358.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:35:05Z","timestamp":1684416905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2016358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,10]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["BFbjc2016358"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2016.358","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,10]]},"assertion":[{"value":"20 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}